Abstract
No public abstract is available from the verified source records.
Amit Goel, Sumit Rungta, Shalimar, Harshita Katiyar, Surender Singh, Amar Deep, Ashish Awasthi, Vikasendu Agarwal, Anurag Kumar Tiwari, Dawesh Prakash Yadav, Sunit Kumar Shukla, Radha Krishan Dhiman, Bharat Bhushan Rewari, Rakesh Aggarwal
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
2024
Unresolved referenced work
2016
National prescribing trends of direct-acting antivirals for hepatitis C
10.1001/jama.2026.3328 · 2026
Number of people treated for hepatitis C virus infection in 2014–2023 and applicable lessons for new HBV and HDV therapies
10.1016/j.jhep.2025.01.013 · 2025
Hepatitis C cascade of care in the direct-acting antivirals era: a meta-analysis
10.1016/j.amepre.2023.06.016 · 2023
Global hepatitis C elimination: updates, challenges, and opportunities from real-world experiences in Europe and North America
10.1097/hep.0000000000001548 · 2025
Progress toward the elimination of hepatitis B and hepatitis C in the country of Georgia, April 2015-April 2024
10.15585/mmwr.mm7330a1 · 2024
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting
10.1016/j.jhep.2019.07.006 · 2019
Adherence to once-daily and twice-daily direct-acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy
10.1093/cid/ciz1089 · 2020
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis
10.1111/jvh.13239 · 2020
Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study
2022
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
10.1053/j.gastro.2004.11.018 · 2005
Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial)
10.1371/journal.pone.0285725 · 2023
Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection
10.1056/nejmoa1702417 · 2018
Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat
10.1002/sim.2244 · 2006
Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection
10.1056/nejmoa1512610 · 2015
Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
10.1056/nejmoa1512612 · 2015
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts
10.1111/liv.14537 · 2020
A cost-effectiveness analysis of shortened direct-acting antiviral treatment in genotype 1 noncirrhotic treatment-naive patients with chronic hepatitis C virus
10.1016/j.jval.2018.12.011 · 2019
Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial
10.7326/m15-1000 · 2015
Efficacy and safety of sofosbuvir-based regimens in hepatitis C patients with decompensated cirrhosis: a systematic review and meta-analysis
2023
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan
10.1111/liv.14849 · 2021
Review article: HCV genotype 3—the new treatment challenge
10.1111/apt.12646 · 2014
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals
10.1016/j.jhep.2017.01.020 · 2017
Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study
10.1016/j.jhep.2023.12.020 · 2024
Real-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy
10.1007/s15010-024-02433-4 · 2025
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial
10.1016/s2468-1253(21)00397-6 · 2022
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
10.1056/nejmoa1402355 · 2014
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection
10.1002/hep.29005 · 2017
No difference in effectiveness of 8 vs 12 weeks of ledipasvir and sofosbuvir for treatment of hepatitis C in black patients
10.1016/j.cgh.2018.03.003 · 2018
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
10.1136/gutjnl-2017-315906 · 2019
EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis
10.1016/j.jhep.2015.04.006 · 2015
No additional external references are available.